Qaieo Frontier
Siloton wins £8.4 million contract to advance handheld eye imaging
On October 14, 2026, Bristol med-tech startup Siloton announced an £8.4 million Innovate UK contract to develop its GiraffeOCT eye-imaging devices and conduct trials. The award funds work toward clinical use; it does not establish an NHS rollout or completed validation. Siloton announcement.
What happened
The UK government's October 13 announcement independently names Siloton among supported projects and describes a handheld scanner intended for eye screening outside specialist hospitals. It places the project within a broader quantum-technology programme, but does not independently confirm Siloton's company-level contract amount.
Siloton says the work covers in-clinic and at-home systems, with Sunderland Specialist Eye Hospital involved in trials of the in-clinic device. Electronics miniaturisation, product development and manufacturing planning are also identified. It describes photonic chips as a way to shrink the equipment. These are development commitments and design goals, not demonstrated outcomes from the new contract.
The recipient supplies the £8.4 million figure and two-year duration. The exact contract execution date, payment schedule and acceptance conditions are not disclosed in the announcements reviewed. An announced contract value is not evidence that the full amount has been paid.
Why it matters
Technical background: Optical coherence tomography, or OCT, uses infrared light to image structures beneath tissue surfaces. The US National Institute of Biomedical Imaging and Bioengineering's explainer, updated September 2025, compares its imaging principle with ultrasound while distinguishing light from sound. It identifies retinal imaging as an established application. This is background on OCT, not an evaluation of GiraffeOCT. The government's quantum programme label does not make every OCT system a new quantum invention.
Frontier analysis: The commercial significance lies in connecting a photonics component to a usable medical product. A smaller optical assembly is one step. Reliable operation, interpretable images, a workable clinical process and repeatable manufacturing are separate questions. A development award creates a defined opportunity to answer them, without answering them in advance.
For a startup, that distinction matters when judging progress. A signed development commitment, a functioning prototype, a completed trial and a customer purchase each reduce different uncertainties. Treating them as interchangeable would obscure both the engineering work remaining and the evidence a future buyer needs.
What comes next
The next reported steps are device development and trials. Future coverage should look for published trial methods and results, the actual conditions tested, manufacturing progress and any separately documented regulatory or purchasing decisions. Those are reporting questions, not confirmed milestones under undisclosed contract terms.
The useful signal will be evidence that a compact photonic system can perform its intended role in practice. Today's news establishes support for that development path, not clinical effectiveness, adoption, payment or financing eligibility.